Vivus REMS modification allows retail Qsymia sales
This article was originally published in Scrip
Executive Summary
Vivus closed out 16 April with a 5.6% boost to its stock price after the company announced mid-day that the US FDA approved a modification to the risk evaluation and mitigation strategy (REMS) for Qsymia (phentermine and topiramate extended-release) to allow for retail pharmacy sales of the weight loss drug.